High performance antibodies ... and more

Blog

Hybridoma technology is the core technique that is used for monoclonal antibody development. By isolating B-cells from mice and fusing them with tumor cells, immortal cell lines are able to be grown and used for production purposes. Learn more about hybridoma protocol on ProSci's blog.

The September Antibody Update includes news on an antibody targetting HIV glycoproteins at different conformations, a paper on humanized monoclonal antibodies against clostridium difficile finishing phase 3 clinical trials, and the study of a human endogenous retrovirus that may reveal understanding of ALS.

Last month, the latest ProSci research on the HIV vaccine development was published in the scientific journal Vaccine. Here is a background on the work ProSci has done developing a vaccine against the HIV glycoproteins.